Skip to content
The Nexus
DossierENTITY

ABS-201

Coverage of ABS-201 in the Nexus archive.

Earliest in view: Jul 1 · 09:25 UTCMost recent: Jul 1 · 09:25 UTC
Co-mentioned in this coverage
Eli Lillyorganization1Absciorganization1androgenetic alopeciatopic1endometriosistopic1GLP-1topic1Isomorphic Labsorganization1Earendil Labsorganization1
Recent coverage
  • HEALTHJul 1 · 09:25 UTCFORTUNE
    Eli Lilly just placed a $40 million bet on the next injectable boom

    Eli Lilly invested $40 million in Absci, an AI-driven drug company developing ABS-201, an injectable antibody targeting androgenetic alopecia and endometriosis. The investment coincided with Absci releasing positive Phase 1 safety data, and both companies aim to leverage direct-to-consumer strategies and AI-designed drugs to disrupt the injectable market.